Sectoral Asset Management Inc Sells 1,071,120 Shares of Amicus Therapeutics, Inc. (FOLD)
Sectoral Asset Management Inc lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 30.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,412,870 shares of the biopharmaceutical company’s stock after selling 1,071,120 shares during the period. Amicus Therapeutics comprises approximately 4.7% of Sectoral Asset Management Inc’s investment portfolio, making the stock its biggest position. Sectoral Asset Management Inc owned 1.45% of Amicus Therapeutics worth $36,386,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in FOLD. Strs Ohio purchased a new position in shares of Amicus Therapeutics during the third quarter valued at approximately $102,000. Teacher Retirement System of Texas boosted its position in shares of Amicus Therapeutics by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 169 shares during the period. Tudor Investment Corp ET AL purchased a new position in shares of Amicus Therapeutics during the second quarter valued at approximately $124,000. Aperio Group LLC boosted its position in shares of Amicus Therapeutics by 13.5% during the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,663 shares during the period. Finally, Zacks Investment Management purchased a new position in shares of Amicus Therapeutics during the second quarter valued at approximately $145,000.
Several research analysts have issued reports on the company. Leerink Swann restated a “buy” rating and set a $20.00 target price (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Robert W. Baird reiterated an “outperform” rating and issued a $16.00 price target on shares of Amicus Therapeutics in a report on Monday, September 25th. Cowen reiterated a “buy” rating and issued a $16.00 price target on shares of Amicus Therapeutics in a report on Monday, August 14th. Zacks Investment Research lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 12th. Finally, Chardan Capital boosted their price target on Amicus Therapeutics from $12.50 to $17.50 and gave the company a “buy” rating in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $17.81.
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $12.89 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics, Inc. has a twelve month low of $4.41 and a twelve month high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). The company had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm’s quarterly revenue was up 419.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.33) EPS. equities research analysts predict that Amicus Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.
In other Amicus Therapeutics news, SVP Daphne Quimi sold 7,000 shares of the company’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $99,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John F. Crowley sold 47,213 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $13.61, for a total value of $642,568.93. Following the sale, the chief executive officer now owns 375,214 shares of the company’s stock, valued at approximately $5,106,662.54. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 680,437 shares of company stock valued at $9,734,522. 3.40% of the stock is owned by company insiders.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.